North America multiple sclerosis drugs market is expected to grow by 3.8% annually in the forecast period and reach $15.65 billion by 2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs.
Highlighted with 28 tables and 51 figures, this 104-page report “North America Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire North America multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Country.
Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Immunomodulators
o Copaxone
o Avonex/Plegridy
o Gilneya
o Tysabri
o Betaseron/Extavia
o Tecifidera
o Rebif
o Ampyra
o Other Immunomodulators
• Immunosuppressants
o Aubagio
o Lemtrada
o Ocrelizumab
o Zinbryta
o Other Immunosuppressants
Based on Drug Class, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Monoclonal Antibodies
• Interferon Beta
• Sphingosine 1 Phosphate Receptor Modulators
• Mixed Polymers
• NF-κB Inhibitor
• Pyrimidine Synthesis Inhibitor
• Corticosteroids
• Adrenocorticotropic Hormone
• Other Drug Classes
Based on Drug Category, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Large-molecule Drugs
• Small-molecule Drugs
Based on Route of Administration, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Oral Administration
• Parenteral Administration
Based on MS Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Relapsing-remitting MS (RRMS)
• Primary-progressive MS (PPMS)
• Secondary-progressive MS (SPMS)
• Progressive-relapsing MS (PRMS)
Based on Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbvie, Inc.
Acorda Therapeutics Inc.
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck KgaA
Mylan NV
Novartis AG
Pfizer Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
